A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

February 3, 2026 updated by: Advenchen Laboratories, LLC

A Phase I/IIa Clinical Trial of AL8326 Tablets Combined With Toripalimab in the Treatment of Advanced Recurrent or Metastatic Solid Tumors

This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

228

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100021
        • Recruiting
        • National GCP Center for Anticancer Drugs,The Independent Ethics Committee
        • Contact:
      • Beijing, Beijing Municipality, China, 100021
        • Recruiting
        • The Cancer Hospital of the Chinese Academy of Medical Sciences
        • Contact:
    • Changsha
      • Hunan, Changsha, China, 410000
        • Recruiting
        • Hunan Cancer Hospital
        • Contact:
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Recruiting
        • Fujian Cancer Hospital
        • Contact:
    • Guangdong
      • Shantou, Guangdong, China, 515000
        • Recruiting
        • Cancer Hospital of Shantou University Medical College
        • Contact:
      • Shaoguan, Guangdong, China, 51200
        • Recruiting
        • Yuebei People's Hospital
        • Contact:
    • Guangxi
      • Guilin, Guangxi, China
        • Recruiting
        • The First Affiliated Hospital of Guilin Medical Universty
        • Contact:
      • Liuchow, Guangxi, China
        • Recruiting
        • Liuzhou Workers' Hospital
        • Contact:
      • Nanning, Guangxi, China, 530021
        • Recruiting
        • Guangxi Medical University Cancer Hospital
        • Contact:
      • Nanning, Guangxi, China, 530000
        • Recruiting
        • The People's Hospital of Guangxi Zhuang Autonomous Region
        • Contact:
    • Henan
      • Zhengzhou, Henan, China, 450000
        • Recruiting
        • Henan Cancer Hospital
        • Contact:
      • Zhengzhou, Henan, China, 450000
        • Recruiting
        • the First Affiliated Hospital of Zhengzhou University
        • Contact:
    • Shanxi
      • Xi’an, Shanxi, China, 710000
        • Recruiting
        • The First Affiliated Hospital Of Xi'an Jiaotong University
        • Contact:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310000
        • Recruiting
        • Zhejiang Cancer Hospital
        • Contact:
      • Hangzhou, Zhejiang, China, 310016
        • Recruiting
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  1. Subjects must be able to understand and voluntarily sign a written informed consent form prior to the initiation of any study-related procedures.
  2. Age ≥ 18 years.

  3. Subjects with histologically confirmed advanced recurrent or metastatic solid tumors who meet one of the following conditions:

    1. Failure of standard therapy (disease progression after treatment or intolerance to treatment toxicity);
    2. no effective treatment available.
    3. Toripalimab monotherapy as a second-line or later standard treatment.
  4. Must have at least one measurable lesion as defined by RECIST 1.1.
  5. Prior cytotoxic chemotherapy must have been completed at least 4 weeks before enrollment, and any toxicities must have recovered to ≤ Grade 1 (except alopecia).
  6. Life expectancy of ≥ 12 weeks at the time of enrollment.
  7. ECOG performance status of 0 or 1.

  8. Adequate organ function:

    1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L (1500/mm³); Platelets ≥ 100 × 10⁹/L; Hemoglobin ≥ 9.0 g/dL.
    2. Renal function: Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or calculated creatinine clearance (Cockcroft-Gault formula) ≥ 60 mL/min.
    3. Hepatic function: Total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN for subjects with Gilbert's syndrome); AST and ALT ≤ 2.5 × ULN in subjects without liver metastases, or ≤ 5 × ULN in subjects with liver metastases.
    4. Coagulation function: International normalized ratio (INR) ≤ 1.5; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  9. Left ventricular ejection fraction (LVEF) > 50% during screening.
  10. Systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg (without medication or controlled with a single agent).
  11. Females: Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment and must agree to use medically acceptable methods of contraception during the treatment period and for 3 months after the last dose; The patient must be non-lactating; Postmenopausal women (≥ 12 months of amenorrhea without other causes) or surgically sterilized (oophorectomy and/or hysterectomy) are not considered of childbearing potential. Their partners must use medically acceptable contraception during the treatment period and for 3 months after the last dose. Males: Surgically sterile or must agree to use medically acceptable contraception during the treatment period and for 3 months after the last dose; Their partners must use medically acceptable contraception during the same period.
  12. Ability and willingness to comply with the study protocol for the duration of the study and with follow-up procedures.

Exclusion Criteria

  1. Received systemic cytotoxic therapy or investigational therapy within 28 days prior to initiation of study treatment, or non-cytotoxic, non-investigational therapy (e.g., radiotherapy, hormone therapy, targeted therapy, immunotherapy) within 14 days prior to initiation of study treatment.
  2. Major surgery (defined as requiring general anesthesia within 28 days before initiation of study treatment, or minor surgery requiring general anesthesia within 7 days before initiation of study treatment).
  3. Pregnant or lactating women.
  4. History of prior or concurrent second primary malignancy that, in the opinion of the investigator or sponsor, may interfere with the assessment of safety or efficacy of the study treatment.
  5. Subjects with active or untreated central nervous system (CNS) metastases; Subjects with stable brain metastases may be enrolled if they meet the following criteria: a) No radiological evidence of progression for ≥ 4 weeks after completion of treatment; b) Completion of treatment ≥ 28 days before the first dose of study drug; c) No requirement for systemic corticosteroids (>10 mg/day prednisone or equivalent) within ≤ 14 days prior to the first dose of study drug.
  6. Active, known, or suspected autoimmune disease or interstitial lung disease.
  7. Requirement for systemic therapy with corticosteroids or other immunosuppressive drugs within 14 days prior to initiation of study treatment.
  8. Peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with risk of perforation; History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to initiation of study treatment.
  9. Untreated deep vein thrombosis (DVT) within the past 6 months. Subjects with DVT treated with therapeutic anticoagulants (excluding therapeutic warfarin) for at least 14 days prior to initiation of study treatment are allowed.
  10. Uncontrolled infection.
  11. New York Heart Association (NYHA) Grade III or greater congestive heart failure.

  12. History of any of the following cardiac conditions within 6 months prior to initiation of study treatment:

    1. Cardiac angioplasty or stenting;
    2. Myocardial infarction;
    3. Unstable angina;
    4. Cerebrovascular accident.
  13. Presence of any unhealed wound, fracture, or ulcer, or symptomatic peripheral vascular disease.
  14. Evidence of hemorrhagic diathesis, coagulation disorder, or clinically significant bleeding (e.g., severe hematuria, gastrointestinal bleeding, hemoptysis) within 6 months prior to initiation of study treatment.
  15. QTcF ≥470 msec on screening ECG per Fridericia's formula.
  16. Urinalysis showing urine protein ≥ ++ and 24-hour urine protein quantification > 1.0 g within 28 days prior to initiation of study treatment.
  17. Positive hepatitis B surface antigen (HBsAg) with HBV-DNA above the lower limit of detection of the local laboratory; Positive hepatitis C antibody (anti-HCV) with HCV-RNA above the lower limit of detection of the local laboratory; Positive syphilis antibody; Positive human immunodeficiency virus (HIV) antibody test.
  18. History of organ transplantation.
  19. Clinical conditions affecting the intake or absorption of AL8326 (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, malabsorption disorders, gastrectomy or small bowel resection).
  20. Use of prohibited concomitant medications within 14 days prior to initiation of study treatment.
  21. Receipt of red blood cell or platelet transfusion within 14 days prior to initiation of study treatment.
  22. Known allergy, hypersensitivity, or intolerance to protein therapies, or history of any severe drug allergy (e.g., anaphylaxis, hepatotoxicity, immune-mediated thrombocytopenia or anemia).
  23. Any severe and/or unstable pre-existing medical, psychiatric, or other condition that may jeopardize subject safety, obtaining informed consent, compliance with study procedures, or achievement of study objectives.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AL8326 plus toripalimab

Phase 1: Cohort 1 will initiate with AL8326 +Toripalimab 240mg multiple dose (28-Day cycles) After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, further cohorts will be enrolled sequentially, following the same 28-day cycle regimen.

Phase 2a: Each subject will receive AL8326 +Toripalimab 240mg of this study for continuous 28-Day/21-Day cycles of therapy. AL8326 is orally administered daily at the RP2D found in Phase 1.
Drug: AL8326 tablets
Tablet: 10mg/tablet; administered orally once daily
Other Names:
  • AL8326
Drug: Toripalimab
240mg Injection solution：21-Day cycles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The first part (Phase I): Phase II recommended dose (RP2D)
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
Determine the Recommended Phase 2 Dose (RP2D) via evaluation of dose limiting toxicity (DLT) events.
At the end of Cycle 1 (each cycle is 28 days)
The second part (Phase IIa):Objective remission rate (ORR)
Time Frame: Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
(ORR):The proportion of subjects achieving complete remission (CR) and partial remission (PR) with optimal efficacy according to RECIST 1.1.
Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The first part (Phase I): Objective remission rate (ORR)
Time Frame: Every 2 cycles,up to 24 months (each cycle is 28 days)
(ORR):The proportion of subjects achieving complete remission (CR) and partial remission (PR) .
Every 2 cycles,up to 24 months (each cycle is 28 days)
The first part (Phase I): Duration of remission (DOR)
Time Frame: Every 2 cycles,up to 24 months (each cycle is 28 days)
(DOR):Description: The time between the start of the first assessment of the tumor as CR or PR and The first assessment of disease progression (PD) or death from any cause.
Every 2 cycles,up to 24 months (each cycle is 28 days)
The first part (Phase I): Disease Control Rate (DCR)
Time Frame: Every 2 cycles,up to 24 months (each cycle is 28 days)
(DCR): The proportion of subjects achieving complete remission (CR), partial remission (PR) and stable disease (SD).
Every 2 cycles,up to 24 months (each cycle is 28 days)
The first part (Phase I): Duration of Disease Control (DDC)
Time Frame: Every 2 cycles,up to 24 months (each cycle is 28 days)
(DDC): The time from the first assessment of the tumor as CR, PR, or SD to the first assessment of disease progression (PD) or death from any cause.
Every 2 cycles,up to 24 months (each cycle is 28 days)
The first part (Phase I): Progression Free Survival (PFS)
Time Frame: Every 2 cycles,up to 24 months (each cycle is 28 days)
(PFS): The period of time between the start of the subject's first dose of medication and the first observation of disease progression (based on imaging) or the occurrence of death due to any cause.
Every 2 cycles,up to 24 months (each cycle is 28 days)
The first part (Phase I): Overall Survival (OS)
Time Frame: Every 2 cycles,up to 24 months (each cycle is 28 days)
(OS): Defined as the time between the date of first dose and death from any cause. Subjects who are alive as of the date of analysis will use and the date they last achieved survival as the cutoff time.
Every 2 cycles,up to 24 months (each cycle is 28 days)
The second part (Phase IIa): Duration of remission (DOR)
Time Frame: Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
(DOR):Description: The time between the start of the first assessment of the tumor as CR or PR and The first assessment of disease progression (PD) or death from any cause.
Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
The second part (Phase IIa): Disease Control Rate (DCR)
Time Frame: Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
(DCR): The proportion of subjects achieving complete remission (CR), partial remission (PR) and stable disease (SD).
Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
The second part (Phase IIa): Duration of Disease Control (DDC)
Time Frame: Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
(DDC): The time from the first assessment of the tumor as CR, PR, or SD to the first assessment of disease progression (PD) or death from any cause.
Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
The second part (Phase IIa): Progression Free Survival (PFS)
Time Frame: Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
(PFS): The period of time between the start of the subject's first dose of medication and the first observation of disease progression (based on imaging) or the occurrence of death due to any cause.
Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
The second part (Phase IIa): Overall Survival (OS)
Time Frame: Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）
(OS): Defined as the time between the date of first dose and death from any cause. Subjects who are alive as of the date of analysis will use and the date they last achieved survival as the cutoff time.
Every 2/3/4 cycles,up to 24 month（each cycle is 21 days）

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Advenchen Laboratories, LLC

Investigators

  • Principal Investigator: Jing wang, Hunan Cancer Hospital
  • Principal Investigator: LingYIng Wu, The Cancer Hospital of the Chinese Academy of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 26, 2021

Primary Completion (Estimated)

November 7, 2029

Study Completion (Estimated)

November 7, 2029

Study Registration Dates

First Submitted

September 28, 2025

First Submitted That Met QC Criteria

February 3, 2026

First Posted (Actual)

February 6, 2026

Study Record Updates

Last Update Posted (Actual)

February 6, 2026

Last Update Submitted That Met QC Criteria

February 3, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AL8326-CN-006

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Solid Tumor

Clinical Trials on AL8326 tablets

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe